You are here: Industry Insights > Rafael

News List

Rafael Holdings Announces Closing of $104.2 Million Private Placement firstwordpharma
August 25, 2021
Rafael Holdings, Inc. (NYSE: RFL) today announced the closing of the previously announced private investment in public equity (PIPE) financing.
Rafael Holdings Announces Appointments to its Board of Directors firstwordpharma
June 15, 2021
Rafael Holdings, Inc., (NYSE: RFL), today announced the appointment of three senior biopharmaceutical leaders to its Board of Directors: Ameet Mallik, Chief Executive Officer of Rafael Holdings; Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc..
Rafael Pharmaceuticals Receives Fast Track Designation for CPI-613 americanpharmaceuticalreview
November 23, 2020
Rafael Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s lead compound, CPI-613® (devimistat), for the treatment of metastatic pancreatic cancer.
Rafael Expands CPI-613 Trial americanpharmaceuticalreview
December 27, 2019
Rafael Pharmaceuticals announced the expansion of its Phase 2 clinical trial of CPI-613® (devimistat) for patients with relapsed or refractory Burkitt’s lymphoma/leukemia.
Rafael Pharma Signs License Agreement with Ono Pharmaceutical contractpharma
June 26, 2019
Aims to accelerate development and commercialization of cancer drug candidate CPI-613 (devimistat) in Japan and other Asian countries.